2921918-19-4
Chemical Structure
Farabursen sodium
Synonym(s): RGLS8429 sodium; RG1015 sodium
- CAS No.: 2921918-19-4
- Formula:C95H107F3N32Na8O50P8S8
- Molecular Weight:3066.4 (free acid)
SMILES: [Farabursen (sodium)]
Biological Activity: Farabursen sodium (RGLS8429 sodium; RG1015 sodium) is a miR-17 inhibitor. Farabursen sodium inhibits the function of the miR-17 family, relieves the inhibitory effect on miR-17 target genes including PKD1 and PKD2, and increases the level of PC1/2. Farabursen sodium slows the growth of renal cysts, reduces the ratio of kidney weight to body weight, and decreases the cyst index and proliferation index. Farabursen sodium is applicable to research related to autosomal dominant polycystic kidney disease[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Farabursen sodium | 93.56% | Farabursen sodium (RGLS8429 sodium; RG1015 sodium) is a miR-17 inhibitor. Farabursen sodium inhibits the function of the miR-17 family, relieves the inhibitory effect on miR-17 target genes including PKD1 and PKD2, and increases the level of PC1/2. Farabursen sodium slows the growth of renal cysts, reduces the ratio of kidney weight to body weight, and decreases the cyst index and proliferation index. Farabursen sodium is applicable to research related to autosomal dominant polycystic kidney disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Yu, Alan S.L.1, et al. Farabursen Increases Urinary Polycystin-1 and Polycystin-2 and Reduces Height-Adjusted Total Kidney Volume Growth in Patients with ADPKD: SA-OR089. Journal of the American Society of Nephrology 36(10S):10.1681/ASN.202527ntvtc3IF: 9.4 Q1 , October 2025.
- [2]. Valencia T, et al. The nucleobase guanine at the 3'-terminus of oligonucleotide RGLS4326 drives off-target AMPAR inhibition and CNS toxicity. Nat Commun. 2025;16(1):10762. Published 2025 Nov 28. [Content Brief]
Keywords
